RPG LIFE SCIENCES LIMITED
QUARTERLY RESULTS FOR
Q1 FY 2013-14
Q/E JUNE 2013
RPG
LIFE SCIENCES has produced improved results for the first quarter
ending June, 2013.
The results are analysed below :
Net
Sales for Q1 FY 14 stand at Rs.62.90
Cr, up by 11.64% from Q4 FY 13(Rs.56.34 Cr); and up by 14.95% from Q1 FY 13
(Rs.54.72 cr).
The
company says :
Subsequent to the pre-approval inspection of the
company's API facility at Navi Mumbai and formulation facility at Ankleshwar by
USFDA, the company has received a notice of non-compliance from USFDA during
the quarter. The company has duly responded to the said notice. However, there
is no immediate business impact of this event as the company does not have any
exports to USA.
Total
Income for Q1 FY 14 stand at Rs.64.18 Cr, up by 9.88% from Q4 FY 13(Rs.58.41 Cr); and up by 15.04% from Q1 FY 13
(Rs. 55.79 cr).
Cost
of materials for Q1 FY 14 stand at Rs.19.10 Cr, up by 57.59% from Q4 FY 13 (Rs.12.12 Cr); and up by 40.96% from Q1 FY 13
(Rs.13.55 cr).Cost of Materials has gone up hugely compared to sales.
Purchases
of stock-in-trade for Q1 FY 14 stand at Rs.4.49 Cr, up by 5.65% from Q4 FY 13(Rs.4.25 Cr);
and up by 25.07% from Q1 FY 13 (Rs.3.59
cr).
Employee
benefits expense for Q1 FY 14 stand at Rs.14.72 Cr, up by8.96%
from Q4 FY 13(Rs.13.51 Cr); and up by 19.97% from Q1 FY 13 (Rs. 12.27 cr).
Depreciation
for
Q1 FY 14 stand at Rs.2.54 Cr, up by 0.4%
from Q4 FY 13(Rs.2.53 Cr); and up by 7.17%
from Q1 FY 13 (Rs.2.37 cr).
Other
expenses for Q1 FY 14 stand at Rs.20.95 Cr, up by 23.96% from Q4 FY 13(Rs.16.90 Cr); and up by 13.24% from Q1 FY 13
(Rs.18.50 cr).
Total
Expenditure for Q1 FY 14 stand at Rs.58.30 Cr, up by 8.53% from Q4 FY
13(Rs.53.72 Cr); and up by 12.81% from Q1
FY 13 (Rs.51.68 cr). Total expenditure has grown but less than proportionately
compared to Sales income and total income.
Profit
before Interest, Dep. & Taxes
for Q1 FY 14 stand at Rs.4.60 Cr, up by 75.57
% from Q4 FY 13(Rs.2.62 Cr); and up by 51.32% from Q1 FY 13 (Rs.3.04 cr).
Exceptional
Income comprises of profit of
Rs. 61.84 Cr on sale of a portion of leasehold land and building thereon and
the company's share of interest income of Rs. 2.42 Cr earned on the sale
consideration deposited by the buyer in an escrow account.
Profit
before tax for Q1 FY 14 stand at Rs.69.37 Cr, up by 1865.16% from Q4 FY 13(Rs.3.53 Cr); and
up by 2334.04% from Q1 FY 13 (Rs.2.85 cr).
Tax
Expenses for Q1 FY 14 stand at Rs.14.68 Cr, compared to Rs.-3.87 Cr in Q4
FY 13; and Rs.0.06 cr in Q1 FY 13.
Net
Profit for Q1 FY 14 stand at Rs.54.69 Cr, up by 639.05% from Q4 FY 13(Rs.7.40 Cr); and up by 1860.22% from Q1 FY 13
(Rs.2.79 cr).
Face
Value- stands at Rs.8/-
Paid-up
Equity for Q1 FY 14 stand at Rs.13.23 Cr
Basic
EPS for Q1 FY 14 stand at Rs.33.07 ,compared to Rs.4.48 in previous Qtr
and Rs.1.69 in corresponding Qtr of last year.
Public
Shareholding (%) for Q1 FY 14 stand at
Rs.43.52
Dividend Declared : RS 1.20/- PER SHARE
RESULTS TABLE
|
RPG LIFE SCIENCES
|
30-Jun-13
|
%DIF QoQ
|
31-Mar-13
|
31-Dec-12
|
30-Sep-12
|
%DIF YoY
|
30-Jun-12
|
|
Net Sales
|
6290
|
11.64
|
5634
|
4809
|
5706
|
14.95
|
5472
|
|
Total Expenditure
|
5830
|
8.53
|
5372
|
5388
|
5616
|
12.81
|
5168
|
|
Profit before Interest, Dep. & Taxes
|
460
|
75.57
|
262
|
-579
|
90
|
51.32
|
304
|
|
Net Profit
|
5469
|
639.05
|
740
|
-609
|
31
|
1860.22
|
279
|
|
Diluted EPS
|
33.07
|
638.17
|
4.48
|
-3.68
|
0.18
|
1856.8
|
1.69
|
|
Net Sales
|
6290
|
11.64
|
5634
|
4809
|
5706
|
14.95
|
5472
|
|
Total Income
|
6418
|
9.88
|
5841
|
4901
|
5843
|
15.04
|
5579
|
|
Changes in inventories
|
-350
|
-179.37
|
441
|
40
|
-352
|
-350
|
140
|
|
Cost of materials
|
1910
|
57.59
|
1212
|
1359
|
1553
|
40.96
|
1355
|
|
Purchases of stock-in-trade
|
449
|
5.65
|
425
|
411
|
685
|
25.07
|
359
|
|
Employee benefits expense
|
1472
|
8.96
|
1351
|
1391
|
1551
|
19.97
|
1227
|
|
Depreciation
|
254
|
0.4
|
253
|
257
|
240
|
7.17
|
237
|
|
Other expenses
|
2095
|
23.96
|
1690
|
1930
|
1939
|
13.24
|
1850
|
|
Total expenses
|
5830
|
8.53
|
5372
|
5388
|
5616
|
12.81
|
5168
|
|
Profit before tax
|
6937
|
1865.16
|
353
|
-635
|
51
|
2334.04
|
285
|
|
Tax Expenses
|
1468
|
-479.33
|
-387
|
-26
|
20
|
24366.67
|
6
|
|
Net Profit
|
5469
|
639.05
|
740
|
-609
|
31
|
1860.22
|
279
|
|
Face Value-Rs
|
8
|
0
|
8
|
8
|
8
|
0
|
8
|
|
Paid-up Equity
|
1323
|
0
|
1323
|
1323
|
1323
|
0
|
1323
|
|
Basic EPS
|
33.07
|
638.17
|
4.48
|
-3.68
|
0.18
|
1856.8
|
1.69
|
|
Public Shareholding (%)
|
43.52
|
0
|
43.52
|
43.52
|
43.52
|
-7.21
|
46.9
|
*
* * E
N D *
* *
